Dr Syed Hussain speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the NEO-BLADE trial which is a phase II randomised placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer.

He reports that the trial failed to reach its primary endpoint of demonstrating an improvement in pathological complete response but did meet the secondary endpoints by demonstrating improvements for nintedanib over placebo in both progression free survival and overall survival.

Dr Hussain explains that previous similar studies had to be stopped early due to toxicity fears however this study was able to demonstrate a well-tolerated regimen with well-balanced toxicities.